{"id":908020,"date":"2025-11-10T20:08:11","date_gmt":"2025-11-11T01:08:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-third-quarter-2025-results\/"},"modified":"2025-11-10T20:08:11","modified_gmt":"2025-11-11T01:08:11","slug":"health-catalyst-reports-third-quarter-2025-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/health-catalyst-reports-third-quarter-2025-results\/","title":{"rendered":"Health Catalyst Reports Third Quarter 2025 Results"},"content":{"rendered":"
\n

SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (\u201cHealth Catalyst,\u201d Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2025.<\/p>\n

\u201cFor the third quarter of 2025, I am pleased by our financial results, including total revenue of $76.3 million and Adjusted EBITDA of $12.0 million, with these results beating our quarterly guidance on each measure,\u201d said Dan Burton, CEO of Health Catalyst. \u201cBy focusing on high-impact solutions with proven ROI and maintaining a commitment to understanding and evolving with our clients, we have reaffirmed our full-year 2025 guidance. We believe our commitment to strategic focus, cost management, and targeted investments positions us to drive sustained value for our clients and shareholders.\u201d<\/p>\n

\n Financial Highlights for the <\/strong>
\n Three Months Ended September 30, 2025<\/strong>\n <\/p>\n

\n
\n Key Financial Metrics<\/em>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n Three Months Ended September 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Year over Year Change<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2024<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n GAAP Financial Measures:<\/strong>\n <\/td>\n\n (in thousands, except percentages, unaudited)<\/strong>\n <\/td>\n<\/tr>\n
Total revenue<\/td>\n$<\/td>\n76,323<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n76,353<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n%<\/td>\n<\/tr>\n
Gross profit<\/td>\n$<\/td>\n29,979<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n27,758<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n8<\/td>\n%<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n39<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n36<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net loss<\/td>\n$<\/td>\n(22,229<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(14,726<\/td>\n)<\/td>\n\u00a0<\/td>\n(51<\/td>\n)%<\/td>\n<\/tr>\n
\n Non-GAAP Financial Measures:<\/strong>
\n
\n (1)<\/strong>
\n <\/sup>\n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Gross Profit<\/td>\n$<\/td>\n40,133<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n36,289<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n11<\/td>\n%<\/td>\n<\/tr>\n
Adjusted Gross Margin<\/td>\n\u00a0<\/td>\n53<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n48<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted EBITDA<\/td>\n$<\/td>\n12,000<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n7,295<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n64<\/td>\n%<\/td>\n<\/tr>\n<\/table>\n

________________________
(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying “Non-GAAP Financial Measures” section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.<\/p>\n

\n Financial Outlook<\/strong>\n <\/p>\n

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.<\/p>\n

For the fourth quarter of 2025, we expect:<\/p>\n